friday rinvoq upadacitinib oral jak inhibitor ra approv label
line expect import mileston key part post humira
strategi separ updat model post better-than-expect result
sale ep estim rais near-term trim long-term
last friday fda approv rinvoq upadacitinib oral jak inhibitor treatment
moderate-to-sever rheumatoid arthriti ra rinvoq also studi ad
sle uc crohn approv along skyrizi risankizumab
psoriasi earlier year import compon post-humira strategi
approv maintain franchis ra psoriasi potenti
expand upon given strong data
rinvoq approv bid dose adult ra patient inadequ
respons intoler methotrex approv base robust select
clinic program test bid dose across phase trial
although file submiss contain data dose pursu
ra indic major pk/pd benefit deriv lower dose across
select program rinvoq met primari secondari endpoint includ superior
dose vs humira select-compar rinvoq launch next week
price
rinvoq label includ class black-box warn seriou infect malign
thrombosi languag regard thrombosi rinvoq label includ dvt pe
speak vte attribut jak inhibitor class gener specif
implic rinvoq cowen pool safeti analysi upadacitinib across select trial found
vte risk bid slightli background rate ra
indic ra remain seen jak induc
similar treatment-associ cv vte risk although expect fda lean cautious
label indic well previous project rinvoq revenu
approxim assum approv indic estim rinvoq sale
leav plenti room upsid
better-than-expect result rais sale ep estim
dime ep versu consensu guidanc
revenu increas versu consensu
guidanc cer chang mix sale increas
ep clip part due higher
sg forecast sale ep sharpli lower given new assumpt
declin humira post launch biosimilar januari similar
eu sale lower ep trim
year project sale ep
impli sale ep cagr respect versu
previous sale ep compound-annual-growth-rate competit versu
last-publish model
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani promis new product
line-up pipelin opportun upward revis sever front dividend
yield group-lead stock attract valu versu group overal
attribut argu purchas share
rinvoq roll-out ra
new indic competit
landscap venclexta/imbruvica
humira sale trend eu
humira sale
humira biosimilar eros less
especi oncolog immunolog
 bolster long-term visibl
humira erod quickli
expect eu and/or launch
oncolog immunolog product
global biopharmaceut compani product use treat rheumatoid
arthriti psoriasi crohn ulcer coliti hcv hematolog tumor among other
humira ra crohn domin product repres total sale
profit also pipelin compound indic phase ii
phase develop process acquir allergan expect close
compani data cowen compani
compani data cowen compani
ww foreign lc ex foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww ip expect hold settlement launch start humira biosimilar launch eu declin year expect foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagi foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launchedandrogel testosteron gel hypergonad market declin gener pressurekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
 combin glecaprevir pi pibrentasvir hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex approv cll delet r/r cll rituxanvenclexta venetoclax select inhibitor cllorilissa- oral gnrh antagonist partial estrogen suppress endometriosi approv uterin fibroib file partnership neurocrin eign lc ex similar lupron zoladexorilissa hold ww right elagolix gnrh antagonistsrova-t meru sclc mainten complet stop futil eign lc ex stem cell technolog solid tumor target peak salesrova-t stemcentrx acq conting payment close rizankizumab guidanc approv psoriasi ph crohn uc ph ii eign lc ex month bi bi receiv mileston royaltiesduodopa infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson supadacitinib- guidanc ra pdufa ph atop dermat ph ii axspa gca eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl myeloma r/r mm w/poma dexveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase zinbryta foreign lc ex fx zinbryta daclizumab withdrawn global march foreign lc ex foreign lc ex world-wide guidanc annual revenu growth cowen
compani data cowen compani
 bimatoprost glaucoma combin lumigan timolol cyclosporin chronic dri eye patent protect total ophthalm franchis remain key franchis new product launch key offset competit dynam moder total botox franchis nervou namenda acquir juli ssri partial agonist mdd merck atyp schizophrenia gx approv assum atyp antipsychot via gedeon richtertot central nervou strong franchis estimate guanyl cyclas agonist ibs-c cic acquir juli short-term treatment od dueoden ulcer acquir aptali mild/moder ulcer proctitit acquir aptali acquir octob exocrin pancreat insuffici due cf acquir aptali acquir furiex viokac pylera rectiv aquadek scandishak salofalk ultresatot strong gi franchis addit est/aptali furiex cowen
compani data cowen compani
lo loestrin gener introduc late decemb women atelvia crinon diafert levosert generess fe metronidazol fibristaltot women market leader excel track record space valsartin comobo pipelin hypertens specif beta blocker via jnjtotal small presenc inject broad-spectrum cephalosporin cap novel cephalosporin/beta lact us rights/azn rowavycaz infecti establish sale forc pipelin product bimatoprost eyelash growth purchas via kythera subment fat remov aczon topic antimicrobi formul acn tazorac medic dermatology/skin dermatolog estimate aczon major driver salin silicon addit product develop juvederm line success revenuearmour dermal cowen
compani data cowen compani
pipelin product rhofad esmya relamorelin oral cgrp acut treatment migrain tavilermid mucin secret analog dri eye would complimentari lifitegrast/restasi rapastinel nmda receptor antagonist treatment-resist depress phase due abicipar longer-dur anti-vegf potenti profil file model assum modest pipelin success cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
